Core Insights - OptimizeRx Corp has announced a data collaboration with Experian to enhance audience measurement for life science marketers, providing a more accurate and transparent view of campaign engagement and effectiveness [1][3] Group 1: Collaboration and Integration - The integration of OptimizeRx's Micro-Neighborhood audience data with Experian's identity graph allows for seamless onboarding and audience activation, improving the ability to reach and measure consumer audiences at scale [1][3] - This collaboration aims to close the visibility gap in direct-to-consumer marketing by providing a reliable methodology for life sciences brands and healthcare marketing agencies [2][3] Group 2: Audience Measurement and Quality - The partnership addresses fragmentation in identity resolution, which has historically limited the visibility of direct-to-consumer campaigns, preventing accurate measurement of marketing impact [2][5] - By improving audience mapping, the collaboration is expected to reduce audience loss during onboarding, thereby increasing total media reach and enhancing audience quality [6][3] Group 3: Micro-Neighborhood Audiences - OptimizeRx's Micro-Neighborhood audiences are created using real-world, privacy-safe clinical and consumer data, allowing for highly precise segmentation at the ZIP+9 level across over 35 million U.S. micro-neighborhoods [4][7] - These audiences are designed to be portable across major media channels, facilitating omnichannel direct-to-consumer advertising for life science marketers [7][8] Group 4: Company Overview - OptimizeRx is a leading healthcare technology company focused on redefining connections between life science brands and patients, utilizing AI-driven tools to enhance engagement [8][9] - Experian is a global data and technology company that provides insights and solutions across various markets, including healthcare, to improve marketing effectiveness and consumer engagement [10][11]

Company Overview - Phreesia, Inc. (NYSE:PHR) is a healthcare technology company focused on enhancing patient intake and engagement while streamlining administrative processes in healthcare settings [1][5] - The company operates in a competitive landscape alongside peers such as Health Catalyst, Veracyte, Accolade, Castle Biosciences, and Personalis, each providing unique solutions in the healthcare technology sector [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is -12.98%, indicating that the company is not generating returns above its cost of capital [2][5] - The company's Weighted Average Cost of Capital (WACC) is 6.71%, leading to a ROIC to WACC ratio of -1.93, which suggests inefficient capital utilization [2][5] Peer Comparison - Health Catalyst has a ROIC of -16.99% and a WACC of 6.12%, resulting in a ROIC to WACC ratio of -2.78, indicating even less efficient capital utilization than Phreesia [3] - Accolade and Personalis also exhibit negative ROIC to WACC ratios of -2.91 and -3.19, respectively, reflecting similar challenges in generating returns above their cost of capital [3] - Castle Biosciences has a ROIC of -4.44% and a WACC of 8.60%, resulting in a ROIC to WACC ratio of -0.52, which, while still negative, is closer to breaking even compared to other peers [4] Industry Challenges - Overall, Phreesia and its peers face significant challenges in generating sufficient returns to cover their cost of capital, which raises concerns for investors [4]

Core Insights - E.F. Hutton & Co. acted as the exclusive placement agent for iSpecimen Inc.'s private placement, raising approximately $5.5 million in gross proceeds before fees and expenses [1][2] Company Overview - iSpecimen operates an online global marketplace that connects scientists with healthcare specimen providers, facilitating efficient access to biospecimens essential for clinical and translational research [2] - The company will issue 6,875 shares of newly designated Series C Convertible Preferred Stock at a purchase price of $800 per share, with each share having a stated value of $1,000 and convertible into common stock at a conversion price equal to 85% of the closing price of the common stock on the trading day before each conversion date [3] Financial Implications - The net proceeds from the offering are intended to support marketing efforts, working capital needs, and general corporate purposes, providing iSpecimen with strategic growth capital while maintaining flexibility for future initiatives [4] Regulatory Aspects - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, sold exclusively to accredited investors, and have not been registered under the Securities Act or applicable state securities laws [5]

Core Insights - TruBridge, Inc. and The Health Management Academy have launched the Rural Health Collaborative to support rural and community hospitals [1] Group 1: Initiative Overview - The Rural Health Collaborative aims to modernize and strengthen rural and community hospitals during a critical period for healthcare delivery [1]

Core Insights - Aclarion, Inc. has initiated patient enrollment in its pivotal CLARITY trial, which aims to evaluate the effectiveness of its Nociscan technology for chronic low back pain [1][2] Group 1: Trial Progress and Enrollment - Northwestern Medicine and Scripps Health have enrolled their first patients, contributing to the overall progress of the CLARITY trial [1][2] - Four clinical sites have enrolled patients, with seven sites having completed necessary regulatory approvals and preparations for patient enrollment [2] - The company aims to enroll approximately 25% of the total 300 patients by the end of Q2 2026, with an initial readout of results expected 90 days after the last patient completes their 3-month follow-up [5][8] Group 2: Clinical Objectives and Methodology - The CLARITY trial is designed to assess whether the integration of Nociscan into surgical planning can improve patient outcomes beyond the current industry benchmark of approximately 54% for chronic low back pain surgeries [4] - The trial will randomize patients between those who are blinded and unblinded to Nociscan results, focusing on surgical planning for Fusion/TDR procedures [4] Group 3: Company Strategy and Leadership - Aclarion has appointed Jason Brosniak as Commercial Director for the Eastern U.S. and Andy Murillo as Director of Market Access to enhance trial enrollment and site expansion [3] - The company views the CLARITY trial as a foundational initiative for value creation, aiming to generate high-quality clinical evidence and support long-term shareholder value [6] Group 4: Market Context and Technology - Chronic low back pain affects an estimated 266 million people globally, highlighting the significance of Aclarion's Nociscan solution, which is the first evidence-supported SaaS platform to help differentiate between painful and nonpainful discs [7] - Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to quantify biomarkers associated with disc pain, potentially improving surgical outcomes for patients with degenerative spine disease [9]

Core Viewpoint - Claritev Corporation is focused on making healthcare more affordable, transparent, and fair for all, and will present at the 44th Annual J.P. Morgan Healthcare Conference [1] Company Participation - Claritev Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference [1] - The management presentation is scheduled for Thursday, January 15, 2026, at 7:30 a.m. PT [1] - A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's website [1]

Core Insights - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the 12 best genomics stocks to invest in [1] Price Adjustments - Canaccord lowered its price objective for Tempus AI, Inc. from $95 to $80 while maintaining a buy rating [2] - BofA also reduced its price estimate for Tempus AI, Inc. from $90 to $80, reaffirming a neutral recommendation [3] Market Outlook - Canaccord noted that the sector momentum from the latter half of 2025 is expected to continue into 2026, particularly in life science instruments and diagnostics [2] - BofA anticipates a rebound in biopharma spending, which is expected to provide significant support for the industry [4] Company Overview - Tempus AI, Inc. is a healthcare technology company that offers molecular genotyping, polymerase chain reaction profiling, next-generation sequencing diagnostics, and various pathology tests to medical professionals and other stakeholders [5]

As filed with the Securities and Exchange Commission on December 30, 2025 Registration No. 333-290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 近日，有雪球网友热议"AI胜过三甲医院普通医生"。对此，知名投资人段永平评论认为："AI绝对胜过平均水准，甚 至可能比一个很贵的私人医生还要更快、更方便，甚至更准确"。近日，AI+医疗健康服务成为热点话题，相关板块 也呈现普涨态势、热度持续上升。 ...

Core Insights - CareCloud is positioning itself for significant growth in 2026 by aligning its leadership to enhance execution, expand margins, and accelerate AI-driven innovation across healthcare markets [1][3][4] Leadership Changes - Effective January 1, 2026, A. Hadi Chaudhry will become Chief Strategy Officer, focusing on enterprise AI vision and initiatives, while Stephen Snyder will continue as CEO, emphasizing disciplined execution and financial performance [2][5] Operational Focus - The leadership evolution reflects a shift towards a more execution-focused operating model, dedicating resources to accelerate AI development as a competitive advantage [3][4] Financial Performance - CareCloud has shown strong momentum, with significant margin expansion and improved cash flow consistency, on track for its first year of positive earnings per share since going public [4][5] Market Expansion - The company has successfully entered the hospital software market through acquisitions, increasing its addressable market and extending its reach across the full care continuum [4][5] AI Strategy - CareCloud aims to leverage AI to reshape healthcare operations, with 2026 seen as a pivotal year for AI adoption among its clients [5] Company Overview - CareCloud provides a suite of AI and technology-enabled solutions to enhance financial and operational performance for over 40,000 providers, focusing on revenue cycle management, practice management, electronic health records, and more [6]